Neoadjuvant Herceptin for Ductal Carcinoma In Situ of the Breast

Status Completed

Clinical Trial Summary

Primary Objectives:

- To determine the effect of a single dose of Herceptin (trastuzumab) on the proliferation rate of Her-2/neu over-expressing ductal carcinoma in situ (DCIS)

- To evaluate the effect of a single dose of Herceptin on the apoptotic index of Her-2/neu over-expressing DCIS

Clinical Trial Description

Herceptin (Trastuzumab) stops or slows the growth of certain breast cancer cells by blocking the chemical signals they need to grow.

As part of your standard care for DCIS, you will have a complete routine physical exam, a mammogram of both breasts, and blood (about 2 tablespoons) will be drawn for routine tests. Some of your leftover breast biopsy tissue will be tested for Her-2/neu expression. Blood will be drawn (about 2-6 teaspoons) to check if your bone marrow (red blood cells), kidney, and liver are functioning well enough to have this treatment. Women who are able to have children must have a negative blood pregnancy test before starting treatment.

If you are eligible to take part in this study, you will receive one dose of trastuzumab at least 2 weeks before your surgery. The dose of trastuzumab will be given intravenously (through a needle in a vein in your arm) as a steady infusion over 90 minutes, on an outpatient basis. You will be checked during the infusion and for 1 hour after it is completed.

You will have routine surgery for DCIS (either segmental mastectomy, mastectomy with or without reconstruction, and possible sentinel lymph node biopsy) approximately 14 to 28 days after being given Herceptin. If a segmental mastectomy was performed as part of our standard practice you will be evaluated by a radiation oncologist following surgery. After your surgery, patients will also be evaluated by a breast medical oncologist to determine if any additional standard therapy is needed.

Tissue that is left over from the original breast biopsy and surgery will be tested for various biomarkers (substances which indicate the severity or spread of cancer), cancer growth rate, and apoptotic index (cell death rate).

This is an investigational study. The FDA has approved trastuzumab for the treatment of breast cancer. Up to 71 patients will take part in this study. All will be enrolled at M. D. Anderson. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00496808
Study type	Interventional
Source	M.D. Anderson Cancer Center
Contact
Status	Completed
Phase	N/A
Start date	March 2005
Completion date	November 2010

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT02889458` - Hong Kong Breast Cancer Study
Completed	`NCT00757302` - Intraoperative Gamma Camera for Breast Cancer Surgery	Phase 3
Active, not recruiting	`NCT03216421` - Intraoperative Radiation Therapy (IORT) in DCIS	N/A
Completed	`NCT03775213` - Acceptability of Active Monitoring (AM) as a Treatment Option for Ductal Carcinoma in Situ (DCIS)	N/A
Active, not recruiting	`NCT00605982` - Breast MRI as a Preoperative Tool for DCIS	N/A
Enrolling by invitation	`NCT04365114` - Patient Outcomes From Second Film-readers and Test Threshold Relaxation in Breast Screening
Completed	`NCT04248179` - The Ultrasound-guided Multiple-injection Costotransverse Block for Mastectomy and Primary Reconstructive Surgery.	Phase 4
Withdrawn	`NCT05032079` - Subzero and Scorpion Trial	N/A
Recruiting	`NCT05218044` - Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ	N/A
Active, not recruiting	`NCT01644669` - Safety and Efficacy Study of the Xoft® Axxent® eBx® IORT System®	N/A
Recruiting	`NCT06133647` - Demographics, Characteristics and Outcomes of Male Breast Cancer Patients at Methodist Health System
Completed	`NCT01815476` - The Prone Breast Radiation Therapy Trial	N/A
Not yet recruiting	`NCT06033092` - Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion	Phase 2
Terminated	`NCT02137252` - Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer	Phase 2
Terminated	`NCT01060345` - A Pilot Study of Chemo-prevention of Green Tea in Women With Ductal Carcinoma in Situ	Phase 2
Recruiting	`NCT00669747` - Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ (DCIS)	Phase 2
Completed	`NCT00742222` - Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer	Phase 4
Active, not recruiting	`NCT02909426` - The Mammography and Ultrasonography STudy for Breast Cancer Screening Effectiveness
Recruiting	`NCT02928978` - Ruxolitinib for Premalignant Breast Disease	Phase 2
Completed	`NCT03375892` - The Use of Deep Inspiration Breath Hold and Prone Irradiation to Decrease Cardiac Radiation Exposure	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.